Millennium Management
LGND icon

Millennium Management’s Ligand Pharmaceuticals LGND Stock Holding History

Millennium Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-71,494
Closed -$9.24M – 4112
2018
Q2 		$9.24M Buy
+71,494
New +$7.98M 0.01% 1371

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's LGND Position: Q2 2025 in Review

Millennium Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 2,577 shares — an estimated $271K sold.

Millennium Management first reported a position in LGND in Q2 2013 and held it in 35 quarters. The position peaked at $74.2M in Q4 2018. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Millennium Management reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Millennium Management sold 2,577 Ligand Pharmaceuticals shares in Q2 2025, an estimated $271K.
  • Millennium Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 35 quarters.
  • Millennium Management's Ligand Pharmaceuticals position peaked at $74.2M in Q4 2018.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.